Category: Uncategorized
Fredrik Frejd, Chief Scientific Officer at Affibody, talked to Drug Discovery World about how the company’s radiotherapeutic candidate could address some of the limitations inherent in current approaches.
The field of targeted radiopharmaceuticals has witnessed remarkable growth in recent years, driven by blockbuster successes of Novartis’ Lutathera (lutetium Lu 177 dotatate) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which together generated over $2 billion in sales in 2024.
This commercial validation has sparked intense interest from both pharmaceutical companies and investors, with multiple billion-dollar acquisitions in the radiopharmaceutical space signalling confidence in the therapeutic approach.
Read the full story here.
CuraCell was recently featured in a wide ranging article in Labiotech on TIL therapy.
While many TIL developers are looking to treat melanoma first, the Swedish biotech is the first to take on prostate cancer. Its prime candidate CC-38 is being developed to address immunologically ‘cold’ solid tumors.
“While CAR-T therapies are clinically established in hematologic cancers, their efficacy in solid tumors – particularly immunologically cold tumors – remains unproven due to challenges such as limited tumor infiltration, antigen heterogeneity, and complex multi-step manufacturing processes. TIL therapies overcome these barriers by using naturally tumour-adapted T cells that can effectively infiltrate the tumour microenvironment and, through their polyclonal nature, recognize multiple tumour antigens, thereby reducing immune escape and improving outcomes in heterogeneous cancers,” said Jonas Båtelson, CEO and co-founder of CuraCell.
For more information on the TIL development landscape, read the whole article here.
In this interview with Clinical Trial Vanguard, Cereno Scientific CEO Sten Sorensen and CMO Rahul Argawal explain that epigenetic modulation of key pathophysiological pathways can do what vasodilation cannot: slow, halt, and potentially reverse the vascular remodelling that drives the relentless progression of pulmonary arterial hypertension (PAH).
Cereno's leaders also talked about the science behind Cereno's approach, the upcoming Phase IIb trial of lead asset CS1, and how this could impact on the lives of those living with PAH on a daily basis.
Read the full article here.
Drug Development & Delivery included an in-depth article on Affibody and its unique approach to radiopharma, and the clinical success of lead RLT candidate, ABY-271, which is currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer.
Read the full article here.
The Board of Directors of Dicot Pharma AB intends to resolve on a rights issue of units, consisting of shares and warrants, corresponding to approximately SEK 210 million to finance the planned Phase IIb study with the drug candidate LIB-01.
The resolution on the Issue is intended to be made pursuant to the authorization proposed to the Annual General Meeting on May 6, 2026. The Issue, including complete terms and conditions, is expected to be resolved by the Board of Directors around May 8, 2026. The Issue is secured to 80 percent, corresponding to SEK 168 million, through subscription undertakings and guarantee commitments from existing shareholders as well as guarantee commitments from Schonfeld Global Master Fund LP, Anavio Capital Partners LLP and Vator Securities.
Read the full release here.
CuraCell TX AB (CuraCell) has announced the appointment of Dr Thomas Jaecklin and Prof Martin Forster to its Board of Directors, further strengthening the company’s leadership as it advances its mission to develop transformative cell-based therapies.
Read the full release here.
CuraCell CEO Jonas Batelson recently spoke to Jonathan Smith, a reporter for Mergermarket, about the companies plans for its next funding round to allow its TIL therapy trials to proceed.
Read the article here.
In Vivo recently published a profile on how Italian biotech AAVantgarde is advancing dual-vector AAV gene therapy for two inherited retinal diseases (Stargardt and Usher syndrome type 1B) using a staged de-risking strategy that leverages data from one programme to underpin the next.
Read the full story here.
Pink Sheet recently featured an interview with Cereno Scientific's CEO, Sten Sorensen, on the benefits of leveraging existing safety data from its broader HDAC platform to streamline the development of its pulmonary hypertension drug, CS014. As the journalst, Aakash Babu states, for cash‑strapped biotechs, this model offers a blueprint for capital‑efficient development.
Read the article here.
A new collaboration between BetterSeeds and Caszyme aims to bypass one of the most persistent constraints in plant gene editing: tissue culture. By combining ultra‑compact Cas12l nucleases with engineered plant viral vectors, the partners say they can deliver precise gene edits directly into crops, cutting time, cost and genotype dependency while making CRISPR more accessible to seed companies.
Read the full article here.